Nichole Carlson
Concepts (557)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoidosis, Pulmonary | 4 | 2026 | 89 | 2.310 |
Why?
| | Sarcoidosis | 3 | 2026 | 162 | 1.740 |
Why?
| | Tomography, X-Ray Computed | 6 | 2026 | 2779 | 1.410 |
Why?
| | Bayes Theorem | 6 | 2020 | 426 | 1.180 |
Why?
| | Luteinizing Hormone | 11 | 2020 | 187 | 1.030 |
Why?
| | Outpatients | 8 | 2025 | 425 | 0.980 |
Why?
| | Models, Statistical | 6 | 2020 | 686 | 0.930 |
Why?
| | Hydrocortisone | 6 | 2015 | 311 | 0.860 |
Why?
| | Radiography, Thoracic | 3 | 2026 | 180 | 0.830 |
Why?
| | Hormones | 3 | 2017 | 138 | 0.800 |
Why?
| | Emphysema | 1 | 2023 | 113 | 0.750 |
Why?
| | Hypothalamo-Hypophyseal System | 7 | 2017 | 198 | 0.690 |
Why?
| | Lung | 6 | 2026 | 4101 | 0.690 |
Why?
| | Pulmonary Emphysema | 1 | 2023 | 310 | 0.650 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2025 | 772 | 0.640 |
Why?
| | Diabetes Complications | 1 | 2022 | 222 | 0.640 |
Why?
| | Data Interpretation, Statistical | 3 | 2017 | 377 | 0.630 |
Why?
| | Disease Susceptibility | 1 | 2021 | 354 | 0.590 |
Why?
| | Metadata | 1 | 2018 | 16 | 0.570 |
Why?
| | State Health Plans | 2 | 2008 | 33 | 0.550 |
Why?
| | Computer Simulation | 4 | 2017 | 1028 | 0.540 |
Why?
| | Follicle Stimulating Hormone | 9 | 2023 | 247 | 0.520 |
Why?
| | Ovary | 3 | 2017 | 227 | 0.510 |
Why?
| | Models, Biological | 3 | 2017 | 1831 | 0.510 |
Why?
| | Adrenocorticotropic Hormone | 2 | 2015 | 147 | 0.490 |
Why?
| | Genome | 1 | 2018 | 309 | 0.480 |
Why?
| | Humans | 100 | 2026 | 143560 | 0.480 |
Why?
| | Reproduction | 1 | 2017 | 206 | 0.480 |
Why?
| | Alzheimer Disease | 5 | 2025 | 606 | 0.460 |
Why?
| | Child Health Services | 2 | 2008 | 197 | 0.460 |
Why?
| | Residence Characteristics | 6 | 2010 | 376 | 0.450 |
Why?
| | Female | 76 | 2026 | 77251 | 0.450 |
Why?
| | Adult | 55 | 2026 | 40013 | 0.450 |
Why?
| | Contraceptives, Oral, Combined | 7 | 2011 | 18 | 0.440 |
Why?
| | Adenosine Monophosphate | 2 | 2025 | 83 | 0.430 |
Why?
| | Health Services for the Aged | 2 | 2019 | 73 | 0.430 |
Why?
| | Biometry | 2 | 2017 | 70 | 0.430 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2021 | 637 | 0.420 |
Why?
| | Middle Aged | 41 | 2026 | 35342 | 0.420 |
Why?
| | Brain Injuries | 5 | 2010 | 506 | 0.420 |
Why?
| | Alanine | 2 | 2025 | 171 | 0.420 |
Why?
| | Software | 2 | 2019 | 687 | 0.420 |
Why?
| | Obesity | 12 | 2023 | 3041 | 0.410 |
Why?
| | Computational Biology | 1 | 2018 | 677 | 0.410 |
Why?
| | Pulsatile Flow | 1 | 2013 | 55 | 0.400 |
Why?
| | Antiparkinson Agents | 3 | 2009 | 40 | 0.400 |
Why?
| | Environment Design | 3 | 2010 | 27 | 0.400 |
Why?
| | Dehydroepiandrosterone | 1 | 2013 | 51 | 0.390 |
Why?
| | Antibodies, Viral | 5 | 2024 | 666 | 0.390 |
Why?
| | Respiratory Function Tests | 3 | 2026 | 560 | 0.390 |
Why?
| | Aged | 30 | 2025 | 25322 | 0.390 |
Why?
| | Antibodies, Monoclonal | 6 | 2025 | 1474 | 0.380 |
Why?
| | Circadian Rhythm | 4 | 2013 | 513 | 0.380 |
Why?
| | Male | 48 | 2026 | 71500 | 0.370 |
Why?
| | Health Services Accessibility | 4 | 2010 | 1049 | 0.360 |
Why?
| | Specimen Handling | 1 | 2013 | 181 | 0.350 |
Why?
| | Antibodies, Neutralizing | 5 | 2025 | 328 | 0.350 |
Why?
| | Gonadotropins | 3 | 2023 | 40 | 0.350 |
Why?
| | Saliva | 1 | 2013 | 247 | 0.350 |
Why?
| | Hospitalization | 9 | 2025 | 2313 | 0.330 |
Why?
| | Antiviral Agents | 3 | 2025 | 764 | 0.320 |
Why?
| | Walking | 4 | 2010 | 557 | 0.320 |
Why?
| | White Matter | 2 | 2023 | 146 | 0.320 |
Why?
| | Levodopa | 2 | 2007 | 40 | 0.310 |
Why?
| | Oregon | 8 | 2011 | 80 | 0.310 |
Why?
| | Hypogonadism | 2 | 2015 | 92 | 0.310 |
Why?
| | Endocrine System | 1 | 2009 | 21 | 0.300 |
Why?
| | Activities of Daily Living | 3 | 2010 | 429 | 0.300 |
Why?
| | Statistics as Topic | 3 | 2025 | 298 | 0.300 |
Why?
| | Parkinson Disease | 4 | 2009 | 576 | 0.290 |
Why?
| | Testosterone | 2 | 2010 | 423 | 0.290 |
Why?
| | Cohort Studies | 8 | 2026 | 5891 | 0.280 |
Why?
| | Technology | 1 | 2009 | 96 | 0.280 |
Why?
| | Prenatal Care | 1 | 2010 | 303 | 0.280 |
Why?
| | Estradiol | 6 | 2023 | 525 | 0.280 |
Why?
| | Cerebral Ventricles | 1 | 2007 | 54 | 0.270 |
Why?
| | Levonorgestrel | 4 | 2011 | 36 | 0.270 |
Why?
| | Cognition Disorders | 3 | 2008 | 523 | 0.260 |
Why?
| | Metrorrhagia | 3 | 2011 | 4 | 0.260 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2022 | 2575 | 0.260 |
Why?
| | Health Behavior | 3 | 2010 | 789 | 0.260 |
Why?
| | Methylphenidate | 1 | 2007 | 46 | 0.250 |
Why?
| | Perception | 2 | 2007 | 378 | 0.250 |
Why?
| | Dopamine Uptake Inhibitors | 1 | 2007 | 61 | 0.250 |
Why?
| | Aged, 80 and over | 12 | 2025 | 8072 | 0.250 |
Why?
| | Smoking Cessation | 1 | 2010 | 435 | 0.250 |
Why?
| | Young Adult | 15 | 2024 | 13972 | 0.250 |
Why?
| | Time Factors | 13 | 2017 | 7031 | 0.230 |
Why?
| | Hyperoxia | 1 | 2026 | 99 | 0.230 |
Why?
| | Poverty | 2 | 2010 | 528 | 0.220 |
Why?
| | Cluster Analysis | 2 | 2023 | 526 | 0.220 |
Why?
| | Gliosis | 2 | 2023 | 29 | 0.220 |
Why?
| | Longitudinal Studies | 10 | 2020 | 3006 | 0.220 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2022 | 3832 | 0.220 |
Why?
| | Health Care Rationing | 1 | 2024 | 60 | 0.210 |
Why?
| | Brain Ischemia | 2 | 2017 | 351 | 0.210 |
Why?
| | Healthcare Disparities | 1 | 2010 | 691 | 0.210 |
Why?
| | Denmark | 2 | 2021 | 49 | 0.200 |
Why?
| | Retrospective Studies | 14 | 2025 | 16741 | 0.200 |
Why?
| | Neurology | 1 | 2025 | 113 | 0.200 |
Why?
| | Medicaid | 1 | 2008 | 460 | 0.200 |
Why?
| | Spirometry | 2 | 2024 | 263 | 0.190 |
Why?
| | Oocytes | 2 | 2020 | 178 | 0.190 |
Why?
| | Risk Factors | 10 | 2022 | 10644 | 0.190 |
Why?
| | Proportional Hazards Models | 4 | 2025 | 1292 | 0.190 |
Why?
| | Body Mass Index | 6 | 2019 | 2429 | 0.180 |
Why?
| | Neuropsychological Tests | 3 | 2025 | 1099 | 0.180 |
Why?
| | Socioeconomic Factors | 5 | 2010 | 1324 | 0.180 |
Why?
| | Benchmarking | 1 | 2023 | 183 | 0.180 |
Why?
| | Markov Chains | 3 | 2017 | 126 | 0.180 |
Why?
| | Monte Carlo Method | 3 | 2017 | 154 | 0.180 |
Why?
| | Aging | 4 | 2008 | 1946 | 0.170 |
Why?
| | Prospective Studies | 9 | 2023 | 7899 | 0.170 |
Why?
| | Cross-Sectional Studies | 12 | 2018 | 5743 | 0.170 |
Why?
| | Disability Evaluation | 4 | 2018 | 304 | 0.170 |
Why?
| | Respiration, Artificial | 1 | 2026 | 705 | 0.170 |
Why?
| | Doxycycline | 2 | 2011 | 60 | 0.170 |
Why?
| | Ethinyl Estradiol | 2 | 2011 | 15 | 0.170 |
Why?
| | Oxygen | 1 | 2026 | 998 | 0.170 |
Why?
| | Oocyte Donation | 1 | 2020 | 4 | 0.170 |
Why?
| | Preimplantation Diagnosis | 1 | 2020 | 6 | 0.170 |
Why?
| | Healthy Aging | 1 | 2021 | 37 | 0.160 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2022 | 100 | 0.160 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2021 | 112 | 0.160 |
Why?
| | Weight Gain | 2 | 2022 | 550 | 0.160 |
Why?
| | Memory, Episodic | 1 | 2021 | 53 | 0.160 |
Why?
| | Prescription Drugs | 1 | 2022 | 114 | 0.160 |
Why?
| | Myocardial Infarction | 2 | 2017 | 1072 | 0.160 |
Why?
| | Reproductive Techniques, Assisted | 1 | 2020 | 43 | 0.160 |
Why?
| | Cytomegalovirus Infections | 1 | 2022 | 199 | 0.160 |
Why?
| | Cross-Over Studies | 6 | 2025 | 583 | 0.160 |
Why?
| | Apomorphine | 3 | 2009 | 7 | 0.160 |
Why?
| | Intensive Care Units | 1 | 2026 | 886 | 0.160 |
Why?
| | Proton Pump Inhibitors | 2 | 2017 | 111 | 0.160 |
Why?
| | Fractals | 1 | 2019 | 8 | 0.160 |
Why?
| | Menstruation | 2 | 1991 | 43 | 0.150 |
Why?
| | Aromatase Inhibitors | 1 | 2020 | 58 | 0.150 |
Why?
| | Comprehensive Health Care | 1 | 2019 | 21 | 0.150 |
Why?
| | Nerve Compression Syndromes | 1 | 1999 | 22 | 0.150 |
Why?
| | Radial Nerve | 1 | 1999 | 10 | 0.150 |
Why?
| | Severity of Illness Index | 7 | 2024 | 2936 | 0.150 |
Why?
| | Reproducibility of Results | 3 | 2025 | 3380 | 0.150 |
Why?
| | Human Growth Hormone | 2 | 2014 | 46 | 0.150 |
Why?
| | Internet | 2 | 2018 | 698 | 0.150 |
Why?
| | Astrocytes | 1 | 2021 | 219 | 0.150 |
Why?
| | Health Status | 3 | 2010 | 824 | 0.150 |
Why?
| | Hypoxia | 1 | 2026 | 1177 | 0.140 |
Why?
| | Hip Fractures | 1 | 2019 | 85 | 0.140 |
Why?
| | Machine Learning | 1 | 2024 | 574 | 0.140 |
Why?
| | Biomedical Research | 1 | 2025 | 699 | 0.140 |
Why?
| | Vital Capacity | 1 | 2019 | 311 | 0.140 |
Why?
| | Quality of Life | 5 | 2018 | 3080 | 0.140 |
Why?
| | Datasets as Topic | 1 | 2018 | 127 | 0.140 |
Why?
| | Bibliometrics | 1 | 2018 | 59 | 0.140 |
Why?
| | Sheep, Domestic | 1 | 2017 | 34 | 0.140 |
Why?
| | Regression Analysis | 2 | 2019 | 1013 | 0.140 |
Why?
| | Case-Control Studies | 5 | 2021 | 3625 | 0.140 |
Why?
| | Anxiety | 1 | 2025 | 1090 | 0.130 |
Why?
| | Contraception | 2 | 1991 | 167 | 0.130 |
Why?
| | Eligibility Determination | 2 | 2008 | 70 | 0.130 |
Why?
| | Reproductive Physiological Phenomena | 1 | 2017 | 1 | 0.130 |
Why?
| | Rhinitis | 2 | 2010 | 173 | 0.130 |
Why?
| | Medically Uninsured | 2 | 2008 | 135 | 0.130 |
Why?
| | Adolescent | 14 | 2024 | 22481 | 0.130 |
Why?
| | Algorithms | 3 | 2017 | 1813 | 0.130 |
Why?
| | Family Planning Services | 2 | 2008 | 90 | 0.130 |
Why?
| | Glomerular Filtration Rate | 1 | 2021 | 775 | 0.130 |
Why?
| | Metabolic Diseases | 1 | 2018 | 116 | 0.130 |
Why?
| | Psychomotor Performance | 3 | 2009 | 328 | 0.130 |
Why?
| | Lactation | 1 | 2018 | 192 | 0.130 |
Why?
| | Premature Birth | 1 | 2020 | 375 | 0.120 |
Why?
| | Hypothyroidism | 2 | 2007 | 74 | 0.120 |
Why?
| | Affect | 3 | 2008 | 315 | 0.120 |
Why?
| | Low Back Pain | 1 | 2018 | 109 | 0.120 |
Why?
| | Double-Blind Method | 7 | 2011 | 2017 | 0.120 |
Why?
| | Endoscopy | 2 | 2010 | 329 | 0.120 |
Why?
| | Antibodies | 1 | 2018 | 402 | 0.120 |
Why?
| | Maternal Nutritional Physiological Phenomena | 1 | 2018 | 182 | 0.120 |
Why?
| | Sinusitis | 2 | 2010 | 239 | 0.120 |
Why?
| | Dietary Fats | 1 | 2018 | 304 | 0.120 |
Why?
| | Pregnancy | 8 | 2023 | 7153 | 0.120 |
Why?
| | Models, Animal | 1 | 2017 | 392 | 0.120 |
Why?
| | Immunologic Memory | 1 | 2018 | 365 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2021 | 378 | 0.120 |
Why?
| | Brain | 6 | 2023 | 2892 | 0.120 |
Why?
| | Personnel Selection | 1 | 2016 | 88 | 0.110 |
Why?
| | Recovery of Function | 2 | 2010 | 702 | 0.110 |
Why?
| | Otolaryngology | 1 | 2016 | 106 | 0.110 |
Why?
| | Patient Dropouts | 1 | 2015 | 65 | 0.110 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2015 | 120 | 0.110 |
Why?
| | Growth Hormone-Secreting Pituitary Adenoma | 1 | 2014 | 12 | 0.110 |
Why?
| | Acromegaly | 1 | 2014 | 16 | 0.110 |
Why?
| | Pulmonary Embolism | 1 | 2017 | 239 | 0.110 |
Why?
| | Pituitary-Adrenal System | 3 | 2013 | 165 | 0.110 |
Why?
| | Menstrual Cycle | 3 | 2011 | 139 | 0.110 |
Why?
| | Fatty Acids, Omega-3 | 1 | 2015 | 142 | 0.110 |
Why?
| | Analysis of Variance | 5 | 2009 | 1314 | 0.110 |
Why?
| | Gonadotropin-Releasing Hormone | 4 | 2020 | 213 | 0.110 |
Why?
| | Breast Feeding | 1 | 2018 | 444 | 0.100 |
Why?
| | Drug Administration Schedule | 4 | 2010 | 773 | 0.100 |
Why?
| | Antibody Formation | 2 | 2022 | 297 | 0.100 |
Why?
| | Biomarkers | 4 | 2021 | 4241 | 0.100 |
Why?
| | Health Care Costs | 1 | 2017 | 423 | 0.100 |
Why?
| | Dementia | 2 | 2008 | 292 | 0.100 |
Why?
| | Secretory Rate | 1 | 2013 | 12 | 0.100 |
Why?
| | Decision Support Systems, Clinical | 1 | 2017 | 270 | 0.100 |
Why?
| | Health Policy | 2 | 2024 | 393 | 0.100 |
Why?
| | Immunoenzyme Techniques | 1 | 2013 | 206 | 0.100 |
Why?
| | Electronics | 1 | 2013 | 74 | 0.100 |
Why?
| | Arthritis, Rheumatoid | 1 | 2022 | 1217 | 0.100 |
Why?
| | Neurosurgical Procedures | 1 | 2014 | 205 | 0.090 |
Why?
| | Arrhythmias, Cardiac | 1 | 2015 | 348 | 0.090 |
Why?
| | Medical Records | 1 | 2013 | 185 | 0.090 |
Why?
| | Interviews as Topic | 3 | 2010 | 868 | 0.090 |
Why?
| | Pandemics | 1 | 2021 | 1668 | 0.090 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2015 | 377 | 0.090 |
Why?
| | Adenoma | 1 | 2014 | 221 | 0.090 |
Why?
| | Age Factors | 8 | 2018 | 3328 | 0.090 |
Why?
| | Ventricular Function, Left | 1 | 2015 | 520 | 0.090 |
Why?
| | Urban Health | 2 | 2009 | 95 | 0.090 |
Why?
| | Treatment Outcome | 8 | 2024 | 11365 | 0.090 |
Why?
| | Education, Medical, Graduate | 1 | 2016 | 541 | 0.090 |
Why?
| | Memory | 3 | 2008 | 266 | 0.090 |
Why?
| | Wakefulness | 1 | 2013 | 170 | 0.090 |
Why?
| | Follow-Up Studies | 5 | 2017 | 5308 | 0.090 |
Why?
| | Progestins | 1 | 2011 | 85 | 0.090 |
Why?
| | Dietary Supplements | 1 | 2015 | 587 | 0.090 |
Why?
| | Equipment Design | 1 | 2013 | 533 | 0.090 |
Why?
| | Amenorrhea | 1 | 2011 | 31 | 0.090 |
Why?
| | Dopamine Agonists | 2 | 2008 | 42 | 0.090 |
Why?
| | Contraceptives, Oral, Hormonal | 2 | 2007 | 30 | 0.080 |
Why?
| | Birth Certificates | 1 | 2010 | 12 | 0.080 |
Why?
| | Estrone | 1 | 2010 | 40 | 0.080 |
Why?
| | Risk Assessment | 2 | 2017 | 3577 | 0.080 |
Why?
| | Birth Rate | 2 | 2020 | 29 | 0.080 |
Why?
| | Insulin | 1 | 2022 | 2497 | 0.080 |
Why?
| | Dihydrotestosterone | 1 | 2010 | 44 | 0.080 |
Why?
| | Electronic Health Records | 3 | 2026 | 1163 | 0.080 |
Why?
| | Cytokines | 2 | 2015 | 2097 | 0.080 |
Why?
| | Cognition | 3 | 2008 | 1261 | 0.080 |
Why?
| | Matrix Metalloproteinase Inhibitors | 1 | 2010 | 14 | 0.080 |
Why?
| | Automobile Driving | 2 | 2010 | 153 | 0.080 |
Why?
| | Geographic Information Systems | 2 | 2010 | 45 | 0.080 |
Why?
| | Pregnancy Rate | 2 | 2020 | 68 | 0.080 |
Why?
| | Live Birth | 2 | 2020 | 73 | 0.080 |
Why?
| | Fertilization in Vitro | 2 | 2020 | 87 | 0.080 |
Why?
| | Diet | 1 | 2018 | 1290 | 0.080 |
Why?
| | Thyroxine | 2 | 2007 | 63 | 0.080 |
Why?
| | Colorado | 3 | 2025 | 4658 | 0.080 |
Why?
| | Cities | 1 | 2010 | 140 | 0.080 |
Why?
| | Sex Factors | 5 | 2018 | 2092 | 0.080 |
Why?
| | Personality | 1 | 2011 | 136 | 0.080 |
Why?
| | Abortion, Induced | 2 | 2008 | 107 | 0.080 |
Why?
| | Electrical Equipment and Supplies | 1 | 2009 | 9 | 0.070 |
Why?
| | United States | 6 | 2020 | 15553 | 0.070 |
Why?
| | Rehabilitation Centers | 1 | 2009 | 39 | 0.070 |
Why?
| | Pattern Recognition, Automated | 1 | 2009 | 74 | 0.070 |
Why?
| | Telecommunications | 1 | 2009 | 21 | 0.070 |
Why?
| | Registries | 1 | 2017 | 2238 | 0.070 |
Why?
| | Independent Living | 1 | 2010 | 113 | 0.070 |
Why?
| | Stroke | 1 | 2017 | 1213 | 0.070 |
Why?
| | Rural Health | 1 | 2009 | 85 | 0.070 |
Why?
| | Progesterone | 3 | 2015 | 258 | 0.070 |
Why?
| | Postmenopause | 1 | 2010 | 377 | 0.070 |
Why?
| | Drug Interactions | 2 | 2007 | 406 | 0.070 |
Why?
| | Mortality | 1 | 2011 | 364 | 0.070 |
Why?
| | Thyrotoxicosis | 1 | 2008 | 8 | 0.070 |
Why?
| | Monitoring, Ambulatory | 1 | 2009 | 90 | 0.070 |
Why?
| | Logistic Models | 2 | 2010 | 2107 | 0.070 |
Why?
| | Ointments | 1 | 2007 | 25 | 0.070 |
Why?
| | Foot | 1 | 2009 | 100 | 0.070 |
Why?
| | Povidone-Iodine | 1 | 2007 | 11 | 0.070 |
Why?
| | Life Change Events | 1 | 2009 | 151 | 0.070 |
Why?
| | Smallpox Vaccine | 1 | 2007 | 24 | 0.070 |
Why?
| | Vaccinia | 1 | 2007 | 22 | 0.070 |
Why?
| | Pregnancy, Unplanned | 1 | 2008 | 47 | 0.070 |
Why?
| | Vaccinia virus | 1 | 2007 | 44 | 0.070 |
Why?
| | Exercise | 3 | 2010 | 2151 | 0.070 |
Why?
| | CD4 Lymphocyte Count | 2 | 2020 | 274 | 0.070 |
Why?
| | Child, Preschool | 4 | 2018 | 11737 | 0.070 |
Why?
| | Parkinsonian Disorders | 1 | 2007 | 43 | 0.070 |
Why?
| | Counseling | 1 | 2010 | 398 | 0.070 |
Why?
| | Dyskinesia, Drug-Induced | 1 | 2007 | 14 | 0.070 |
Why?
| | Atrophy | 1 | 2007 | 197 | 0.060 |
Why?
| | Disease Progression | 3 | 2015 | 2856 | 0.060 |
Why?
| | Population Surveillance | 1 | 2010 | 488 | 0.060 |
Why?
| | Antigens, Bacterial | 1 | 2007 | 126 | 0.060 |
Why?
| | Antibodies, Bacterial | 1 | 2007 | 146 | 0.060 |
Why?
| | Antigens, Viral | 1 | 2007 | 179 | 0.060 |
Why?
| | Awareness | 1 | 2007 | 102 | 0.060 |
Why?
| | Movement | 1 | 2009 | 291 | 0.060 |
Why?
| | Albumins | 1 | 2007 | 114 | 0.060 |
Why?
| | Time Perception | 1 | 2007 | 33 | 0.060 |
Why?
| | Tremor | 1 | 2007 | 97 | 0.060 |
Why?
| | Wounds, Gunshot | 1 | 2009 | 251 | 0.060 |
Why?
| | Blood-Brain Barrier | 1 | 2007 | 150 | 0.060 |
Why?
| | Suicide, Attempted | 1 | 2009 | 398 | 0.060 |
Why?
| | Internship and Residency | 1 | 2016 | 1250 | 0.060 |
Why?
| | Cost-Benefit Analysis | 1 | 2009 | 621 | 0.060 |
Why?
| | Hospitals, Community | 1 | 2026 | 65 | 0.060 |
Why?
| | Pragmatic Clinical Trials as Topic | 1 | 2026 | 132 | 0.060 |
Why?
| | Utah | 1 | 2025 | 82 | 0.060 |
Why?
| | Paroxetine | 1 | 2005 | 9 | 0.060 |
Why?
| | Infant | 3 | 2010 | 9981 | 0.060 |
Why?
| | Treatment Failure | 2 | 2022 | 357 | 0.060 |
Why?
| | Animals | 7 | 2023 | 38010 | 0.060 |
Why?
| | Emergency Service, Hospital | 1 | 2017 | 2270 | 0.060 |
Why?
| | Attitude to Health | 1 | 2008 | 451 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2026 | 389 | 0.050 |
Why?
| | Neurologic Examination | 2 | 2008 | 127 | 0.050 |
Why?
| | Administration, Oral | 1 | 2007 | 842 | 0.050 |
Why?
| | Pulmonary Diffusing Capacity | 1 | 2024 | 76 | 0.050 |
Why?
| | Sensitivity and Specificity | 1 | 2009 | 1984 | 0.050 |
Why?
| | Sexual Behavior | 1 | 2008 | 498 | 0.050 |
Why?
| | Health Promotion | 1 | 2010 | 765 | 0.050 |
Why?
| | Video Recording | 1 | 2025 | 207 | 0.050 |
Why?
| | Research Design | 2 | 2026 | 1123 | 0.050 |
Why?
| | Likelihood Functions | 2 | 2017 | 144 | 0.050 |
Why?
| | United States Food and Drug Administration | 1 | 2024 | 202 | 0.050 |
Why?
| | Patient Compliance | 1 | 2008 | 617 | 0.050 |
Why?
| | Follicle Stimulating Hormone, Human | 1 | 2023 | 12 | 0.050 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2026 | 1671 | 0.050 |
Why?
| | Child | 5 | 2018 | 22725 | 0.050 |
Why?
| | Linear Models | 2 | 2020 | 858 | 0.050 |
Why?
| | Family | 1 | 2008 | 683 | 0.050 |
Why?
| | Neurites | 1 | 2023 | 52 | 0.050 |
Why?
| | Diffusion Tensor Imaging | 1 | 2023 | 75 | 0.050 |
Why?
| | Motor Activity | 1 | 2007 | 721 | 0.050 |
Why?
| | Physical Fitness | 1 | 2004 | 207 | 0.050 |
Why?
| | Ritonavir | 1 | 2023 | 72 | 0.050 |
Why?
| | Temporomandibular Joint Dysfunction Syndrome | 1 | 2002 | 3 | 0.050 |
Why?
| | Facial Pain | 1 | 2002 | 13 | 0.050 |
Why?
| | Vaccines | 1 | 2007 | 410 | 0.050 |
Why?
| | Emotions | 1 | 2007 | 581 | 0.050 |
Why?
| | Urban Population | 1 | 2025 | 491 | 0.050 |
Why?
| | Physical Examination | 2 | 2018 | 245 | 0.050 |
Why?
| | Sex Characteristics | 1 | 2007 | 793 | 0.050 |
Why?
| | Acids | 1 | 2002 | 18 | 0.050 |
Why?
| | B-Lymphocytes | 1 | 2007 | 884 | 0.050 |
Why?
| | Administration, Cutaneous | 2 | 2015 | 129 | 0.050 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2023 | 156 | 0.050 |
Why?
| | Odds Ratio | 3 | 2010 | 1060 | 0.040 |
Why?
| | Faculty, Medical | 1 | 2025 | 297 | 0.040 |
Why?
| | Practice Patterns, Physicians' | 1 | 2011 | 1362 | 0.040 |
Why?
| | Ovarian Follicle | 1 | 2002 | 72 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 3 | 2008 | 3798 | 0.040 |
Why?
| | Rheumatoid Factor | 1 | 2022 | 176 | 0.040 |
Why?
| | Herpesvirus 4, Human | 1 | 2022 | 169 | 0.040 |
Why?
| | Neuroimaging | 1 | 2023 | 282 | 0.040 |
Why?
| | Hospital Mortality | 1 | 2025 | 962 | 0.040 |
Why?
| | Anti-Bacterial Agents | 1 | 2011 | 1906 | 0.040 |
Why?
| | Oocyte Retrieval | 1 | 2020 | 12 | 0.040 |
Why?
| | Leadership | 1 | 2025 | 397 | 0.040 |
Why?
| | Puberty | 1 | 2002 | 158 | 0.040 |
Why?
| | Pregnancy, Multiple | 1 | 2020 | 18 | 0.040 |
Why?
| | Immunoglobulin M | 1 | 2022 | 288 | 0.040 |
Why?
| | Anti-Citrullinated Protein Antibodies | 1 | 2022 | 125 | 0.040 |
Why?
| | Immunoglobulin A | 1 | 2022 | 218 | 0.040 |
Why?
| | Leptin | 1 | 2002 | 239 | 0.040 |
Why?
| | Patient Acceptance of Health Care | 1 | 2007 | 884 | 0.040 |
Why?
| | Blastocyst | 1 | 2020 | 48 | 0.040 |
Why?
| | Embryo Transfer | 1 | 2020 | 37 | 0.040 |
Why?
| | Fasting | 1 | 2002 | 284 | 0.040 |
Why?
| | Breast Neoplasms | 2 | 2011 | 2318 | 0.040 |
Why?
| | Prostaglandins | 1 | 2000 | 97 | 0.040 |
Why?
| | Radionuclide Imaging | 1 | 2019 | 117 | 0.040 |
Why?
| | Surveys and Questionnaires | 3 | 2025 | 6025 | 0.040 |
Why?
| | Critical Illness | 1 | 2026 | 869 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2009 | 2056 | 0.040 |
Why?
| | Endotoxins | 1 | 2000 | 213 | 0.040 |
Why?
| | Oligodendroglia | 1 | 2001 | 181 | 0.040 |
Why?
| | Vaccination | 2 | 2024 | 1484 | 0.040 |
Why?
| | Decompression, Surgical | 1 | 1999 | 116 | 0.040 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2007 | 1413 | 0.040 |
Why?
| | Receptors, Nicotinic | 1 | 2001 | 344 | 0.040 |
Why?
| | Immunization, Secondary | 1 | 2018 | 92 | 0.030 |
Why?
| | Depression | 1 | 2008 | 1512 | 0.030 |
Why?
| | Predictive Value of Tests | 2 | 2018 | 2086 | 0.030 |
Why?
| | Controlled Before-After Studies | 1 | 2017 | 15 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2022 | 898 | 0.030 |
Why?
| | Depressive Disorder | 1 | 2000 | 376 | 0.030 |
Why?
| | Milk | 1 | 2018 | 124 | 0.030 |
Why?
| | Confidence Intervals | 2 | 2008 | 332 | 0.030 |
Why?
| | Biostatistics | 1 | 2017 | 18 | 0.030 |
Why?
| | Protons | 1 | 2017 | 96 | 0.030 |
Why?
| | Genetic Testing | 1 | 2020 | 474 | 0.030 |
Why?
| | Psychological Tests | 1 | 2018 | 133 | 0.030 |
Why?
| | Signal-To-Noise Ratio | 1 | 2017 | 69 | 0.030 |
Why?
| | Incidence | 2 | 2017 | 2844 | 0.030 |
Why?
| | Electromyography | 1 | 1999 | 413 | 0.030 |
Why?
| | Thyrotropin | 2 | 2007 | 116 | 0.030 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2022 | 927 | 0.030 |
Why?
| | Diet, High-Fat | 1 | 2018 | 260 | 0.030 |
Why?
| | Stem Cells | 1 | 2001 | 619 | 0.030 |
Why?
| | Health Surveys | 2 | 2009 | 512 | 0.030 |
Why?
| | Lipopolysaccharides | 1 | 2000 | 861 | 0.030 |
Why?
| | Survival Analysis | 1 | 2019 | 1332 | 0.030 |
Why?
| | Drug Combinations | 2 | 2011 | 372 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 856 | 0.030 |
Why?
| | Viruses | 1 | 2018 | 164 | 0.030 |
Why?
| | Telemedicine | 1 | 2025 | 926 | 0.030 |
Why?
| | Dilatation, Pathologic | 1 | 2015 | 62 | 0.030 |
Why?
| | Gastrointestinal Diseases | 1 | 2017 | 211 | 0.030 |
Why?
| | Escherichia coli | 1 | 2000 | 834 | 0.030 |
Why?
| | Fatty Liver | 1 | 2018 | 249 | 0.030 |
Why?
| | Neoplasms | 1 | 2011 | 2804 | 0.030 |
Why?
| | Systole | 1 | 2015 | 175 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 1999 | 1504 | 0.030 |
Why?
| | Drug Users | 1 | 2015 | 42 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2015 | 1226 | 0.030 |
Why?
| | Electric Countershock | 1 | 2015 | 115 | 0.030 |
Why?
| | Absorptiometry, Photon | 1 | 2015 | 272 | 0.030 |
Why?
| | Risk | 1 | 2017 | 906 | 0.030 |
Why?
| | Chi-Square Distribution | 1 | 2015 | 527 | 0.030 |
Why?
| | Phospholipids | 1 | 2015 | 212 | 0.030 |
Why?
| | Death, Sudden, Cardiac | 1 | 2015 | 194 | 0.030 |
Why?
| | Psychometrics | 1 | 2018 | 739 | 0.030 |
Why?
| | Substance Abuse, Intravenous | 1 | 2015 | 125 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2015 | 720 | 0.030 |
Why?
| | Interleukin-1beta | 1 | 2015 | 392 | 0.030 |
Why?
| | Adipose Tissue | 1 | 2018 | 654 | 0.030 |
Why?
| | Phenotype | 1 | 2022 | 3211 | 0.030 |
Why?
| | Analgesics, Opioid | 1 | 2022 | 1127 | 0.020 |
Why?
| | Disease Models, Animal | 2 | 2018 | 4522 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2015 | 921 | 0.020 |
Why?
| | Follicular Phase | 2 | 2004 | 39 | 0.020 |
Why?
| | Estrogens | 1 | 2015 | 372 | 0.020 |
Why?
| | Mice, Inbred C57BL | 2 | 2018 | 6043 | 0.020 |
Why?
| | Fatty Acids | 1 | 2015 | 452 | 0.020 |
Why?
| | Feeding Behavior | 1 | 2018 | 688 | 0.020 |
Why?
| | Defibrillators, Implantable | 1 | 2015 | 318 | 0.020 |
Why?
| | Mothers | 1 | 2018 | 783 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2015 | 1510 | 0.020 |
Why?
| | Periodicity | 2 | 2001 | 56 | 0.020 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2018 | 681 | 0.020 |
Why?
| | Prognosis | 1 | 1999 | 4152 | 0.020 |
Why?
| | Abbreviated Injury Scale | 1 | 2010 | 24 | 0.020 |
Why?
| | Trauma Severity Indices | 1 | 2010 | 111 | 0.020 |
Why?
| | Nasal Polyps | 1 | 2010 | 62 | 0.020 |
Why?
| | Amides | 1 | 2010 | 97 | 0.020 |
Why?
| | Life Expectancy | 1 | 2010 | 73 | 0.020 |
Why?
| | Heart-Assist Devices | 1 | 2015 | 572 | 0.020 |
Why?
| | Reference Values | 1 | 2010 | 811 | 0.020 |
Why?
| | Income | 1 | 2010 | 198 | 0.020 |
Why?
| | Glasgow Coma Scale | 1 | 2010 | 214 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2020 | 6366 | 0.020 |
Why?
| | Obstetrics | 1 | 2011 | 177 | 0.020 |
Why?
| | Norgestrel | 1 | 1988 | 2 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2015 | 1130 | 0.020 |
Why?
| | Heart Transplantation | 1 | 2015 | 726 | 0.020 |
Why?
| | Medroxyprogesterone | 1 | 1988 | 12 | 0.020 |
Why?
| | Administration, Intravaginal | 1 | 1988 | 18 | 0.020 |
Why?
| | Chromatography, Liquid | 1 | 2010 | 453 | 0.020 |
Why?
| | Family Characteristics | 1 | 2010 | 192 | 0.020 |
Why?
| | Gynecology | 1 | 2011 | 180 | 0.020 |
Why?
| | Medroxyprogesterone Acetate | 1 | 1988 | 37 | 0.020 |
Why?
| | Poverty Areas | 1 | 2008 | 42 | 0.020 |
Why?
| | Thyroid Function Tests | 1 | 2008 | 14 | 0.020 |
Why?
| | Single-Blind Method | 1 | 2009 | 294 | 0.020 |
Why?
| | Parity | 1 | 1988 | 110 | 0.020 |
Why?
| | Receptors, Dopamine | 1 | 2008 | 18 | 0.020 |
Why?
| | Intelligence Tests | 1 | 2008 | 63 | 0.020 |
Why?
| | Sheep | 2 | 2002 | 885 | 0.020 |
Why?
| | Benzodioxoles | 1 | 2010 | 144 | 0.020 |
Why?
| | Smallpox | 1 | 2007 | 10 | 0.020 |
Why?
| | Employment | 1 | 2010 | 182 | 0.020 |
Why?
| | Galvanic Skin Response | 1 | 2007 | 26 | 0.020 |
Why?
| | Diphtheria | 1 | 2007 | 22 | 0.020 |
Why?
| | Tetanus | 1 | 2007 | 27 | 0.020 |
Why?
| | Personal Satisfaction | 1 | 2010 | 218 | 0.020 |
Why?
| | Virus Shedding | 1 | 2007 | 48 | 0.020 |
Why?
| | Half-Life | 1 | 2007 | 147 | 0.020 |
Why?
| | Contraindications | 1 | 2007 | 86 | 0.020 |
Why?
| | Commerce | 1 | 2008 | 77 | 0.020 |
Why?
| | Educational Status | 1 | 2010 | 464 | 0.020 |
Why?
| | Lymphocyte Count | 1 | 2007 | 167 | 0.020 |
Why?
| | Cause of Death | 1 | 2010 | 459 | 0.020 |
Why?
| | Plasma Cells | 1 | 2007 | 74 | 0.020 |
Why?
| | Tandem Mass Spectrometry | 1 | 2010 | 566 | 0.020 |
Why?
| | Nerve Fibers, Myelinated | 1 | 2007 | 47 | 0.020 |
Why?
| | Seroepidemiologic Studies | 1 | 2007 | 171 | 0.020 |
Why?
| | Neoplasm Invasiveness | 1 | 2009 | 518 | 0.020 |
Why?
| | Triiodothyronine | 1 | 2007 | 50 | 0.020 |
Why?
| | Apolipoproteins E | 1 | 2007 | 91 | 0.020 |
Why?
| | Family Practice | 1 | 2011 | 442 | 0.020 |
Why?
| | Photic Stimulation | 1 | 2007 | 258 | 0.020 |
Why?
| | Research | 1 | 2010 | 438 | 0.020 |
Why?
| | Thyroid Hormones | 1 | 2007 | 68 | 0.020 |
Why?
| | Thyroid Gland | 1 | 2007 | 93 | 0.020 |
Why?
| | Cerebrovascular Disorders | 1 | 2007 | 100 | 0.020 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2007 | 228 | 0.020 |
Why?
| | Neural Inhibition | 1 | 2007 | 176 | 0.020 |
Why?
| | Age of Onset | 1 | 2008 | 548 | 0.020 |
Why?
| | Safety | 1 | 2008 | 357 | 0.020 |
Why?
| | Motor Skills | 1 | 2007 | 105 | 0.010 |
Why?
| | Patient Satisfaction | 1 | 2010 | 700 | 0.010 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2008 | 553 | 0.010 |
Why?
| | Dopamine Agents | 1 | 2005 | 22 | 0.010 |
Why?
| | Mental Recall | 1 | 2007 | 213 | 0.010 |
Why?
| | Virus Diseases | 1 | 2007 | 218 | 0.010 |
Why?
| | Down-Regulation | 1 | 2007 | 644 | 0.010 |
Why?
| | Gait Disorders, Neurologic | 1 | 2005 | 46 | 0.010 |
Why?
| | Comorbidity | 1 | 2010 | 1678 | 0.010 |
Why?
| | Self Efficacy | 1 | 2008 | 409 | 0.010 |
Why?
| | Dizziness | 1 | 2005 | 95 | 0.010 |
Why?
| | Inpatients | 1 | 2009 | 521 | 0.010 |
Why?
| | Memory, Short-Term | 1 | 2007 | 268 | 0.010 |
Why?
| | Vestibular Diseases | 1 | 2005 | 53 | 0.010 |
Why?
| | Presynaptic Terminals | 1 | 2005 | 94 | 0.010 |
Why?
| | Diet Records | 1 | 2004 | 84 | 0.010 |
Why?
| | Menarche | 1 | 2004 | 53 | 0.010 |
Why?
| | Length of Stay | 1 | 2009 | 1279 | 0.010 |
Why?
| | Chronic Disease | 1 | 2010 | 1824 | 0.010 |
Why?
| | Overweight | 1 | 2008 | 598 | 0.010 |
Why?
| | Serotonin | 1 | 2005 | 290 | 0.010 |
Why?
| | Skin | 1 | 2007 | 774 | 0.010 |
Why?
| | Stress, Psychological | 1 | 2011 | 1134 | 0.010 |
Why?
| | Dopamine | 1 | 2005 | 306 | 0.010 |
Why?
| | Follicular Fluid | 1 | 2002 | 5 | 0.010 |
Why?
| | Adrenal Cortex | 1 | 2002 | 33 | 0.010 |
Why?
| | Neuraminidase | 1 | 2002 | 25 | 0.010 |
Why?
| | Contraceptives, Oral | 1 | 2002 | 38 | 0.010 |
Why?
| | Heart Failure | 1 | 2015 | 2131 | 0.010 |
Why?
| | Hormone Antagonists | 1 | 2002 | 34 | 0.010 |
Why?
| | Osmolar Concentration | 1 | 2002 | 166 | 0.010 |
Why?
| | Accidental Falls | 1 | 2005 | 234 | 0.010 |
Why?
| | Dipeptides | 1 | 2002 | 56 | 0.010 |
Why?
| | Thinness | 1 | 2002 | 98 | 0.010 |
Why?
| | Dihydro-beta-Erythroidine | 1 | 2001 | 6 | 0.010 |
Why?
| | Fura-2 | 1 | 2001 | 12 | 0.010 |
Why?
| | Postprandial Period | 1 | 2002 | 116 | 0.010 |
Why?
| | Nifedipine | 1 | 2001 | 29 | 0.010 |
Why?
| | Caregivers | 1 | 2010 | 970 | 0.010 |
Why?
| | Nicotinic Antagonists | 1 | 2001 | 36 | 0.010 |
Why?
| | Pituitary Gland | 1 | 2002 | 151 | 0.010 |
Why?
| | Energy Intake | 1 | 2004 | 513 | 0.010 |
Why?
| | Oxygen Consumption | 1 | 2004 | 718 | 0.010 |
Why?
| | Luteal Phase | 1 | 2000 | 46 | 0.010 |
Why?
| | Area Under Curve | 1 | 2001 | 327 | 0.010 |
Why?
| | Prostaglandin Antagonists | 1 | 2000 | 3 | 0.010 |
Why?
| | Flurbiprofen | 1 | 2000 | 3 | 0.010 |
Why?
| | Depression, Chemical | 1 | 2000 | 19 | 0.010 |
Why?
| | Protein Isoforms | 1 | 2002 | 404 | 0.010 |
Why?
| | HIV Infections | 1 | 2015 | 3013 | 0.010 |
Why?
| | Calcium Channel Blockers | 1 | 2001 | 175 | 0.010 |
Why?
| | Pain Measurement | 1 | 2002 | 558 | 0.010 |
Why?
| | Fluorescent Dyes | 1 | 2001 | 325 | 0.010 |
Why?
| | Fever | 1 | 2000 | 310 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2007 | 2417 | 0.010 |
Why?
| | Hypertension | 1 | 2007 | 1260 | 0.010 |
Why?
| | Gene Expression | 1 | 2001 | 1505 | 0.010 |
Why?
| | Calcium | 1 | 2001 | 1183 | 0.010 |
Why?
| | Sleep | 1 | 2002 | 889 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2001 | 4182 | 0.010 |
Why?
| | Rats | 1 | 2001 | 5610 | 0.010 |
Why?
| | Neurons | 1 | 2001 | 1636 | 0.010 |
Why?
| | Mice | 1 | 2007 | 18378 | 0.000 |
Why?
|
|
Carlson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|